Table 3.
Sensitivity Analysis Results for Relationships Between Sleep Duration and Cardiometabolic Risk in the Subsample of Participants not Taking Antihypertensive Medication (n = 1173, 96.6% of the Sample)
| Reported sleep duration, hours | Individual components of the metabolic syndrome |
|||||
|---|---|---|---|---|---|---|
| Metabolic syndrome OR (95% CI) | Central adiposity criterion OR (95% CI) | Glucose criterion OR (95% CI) | Blood pressure criterion OR (95% CI) | Triglycerides criterion OR (95% CI) | HDL criterion OR (95% CI) | |
| < 6 | 1.76 (1.13–2.74) | 1.75 (1.19–2.56) | 1.76 (1.19–2.60) | 1.13 (0.76–1.68) | 1.29 (0.82–2.03) | 1.31 (0.87–1.95) |
| 6 – < 7 | 1.47 (1.03–2.11) | 1.64 (1.22–2.22) | 1.06 (0.77–1.45) | 0.96 (0.70–1.31) | 1.51 (1.07–2.13) | 1.26 (0.92–1.73) |
| 7– 8 | Ref | Ref | Ref | Ref | Ref | Ref |
| > 8 | 1.65 (0.91–3.00) | 1.41 (0.85–2.34) | 1.56 (0.93–2.63) | 0.87 (0.49–1.54) | 0.91 (0.48–1.74) | 1.77 (1.08–2.89) |
Sleep duration = 7–8 hours as referent; covariates included age, sex, race, educational attainment, smoker, physical activity, low-density lipoprotein (LDL) cholesterol and symptoms of depression (odds ratio [OR] and 95% confidence interval [CI] not shown). HDL refers to high-density lipoprotein.